IBS: ABx trial shows lasting improvements

Discussion in 'Fibromyalgia Main Forum' started by tansy, Nov 9, 2005.

  1. tansy

    tansy New Member

    Irritable Bowel Syndrome Study Shows That Targeted Antibiotics Lead To
    Long-lasting Improvement In Symptoms

    Researchers at Cedars-Sinai Medical Center have found that a nonabsorbable
    antibiotic one that stays in the gut may be an effective long-term
    treatment for irritable bowel syndrome (IBS), a disease affecting more than
    an estimated 20 percent of Americans. The findings, which showed that
    participants benefited from the antibiotic use even after the course of
    treatment ended, support previously published research identifying small
    intestine bacterial overgrowth (SIBO) as a possible cause of the disease.

    The research was presented at the recent American College of
    Gastroenterology's annual meeting in Honolulu, HI.

    "This study is important as it is the first to show that the use of
    targeted antibiotics results in a more significant and long-lasting
    improvement in IBS symptoms," said Mark Pimentel, M.D., first author on the
    study and director of the GI Motility Program at Cedars-Sinai. "These
    results clearly show that antibiotics offer a new treatment approach and a
    new hope for people with IBS."

    The randomized, double blind study involved 87 patients. Those on the
    rifaximin experienced a 37 percent overall improvement of their IBS
    symptoms as compared to 23 percent on the placebo. Among study subjects
    whose primary symptom was diarrhea, those on the antibiotic showed more
    than twice the improvement of those on the placebo (49 percent vs. 23
    percent). Patients received the drug (or placebo) for 10 days and were then
    followed for a total of 10 weeks. Participants kept a stool diary, took a
    questionnaire and were given methane breath tests. The positive effects of
    the drug were shown to continue throughout most of the 10-week study, not
    just during the actual antibiotic course.

    Because the cause of IBS has been elusive, treatments for the disease have
    historically focused on reducing its symptoms diarrhea and
    constipation by giving medications that either slow or speed up the
    digestive process. In 2000, Pimentel linked bloating, the most common
    symptom of IBS, to bacterial fermentation, showing that small intestine
    bacteria overgrowth (SIBO) may be the causative factor in IBS (The American
    Journal of Gastroenterology, Dec. 2000).

    To show evidence of small intestine bacterial overgrowth, participants in
    both studies were given a lactulose breath test, which monitors the level
    of hydrogen and methane (the gases emitted by fermented bacteria) on the
    breath. In the first study, an abnormal breath methane profile was shown to
    be 100 percent predictive of constipation-predominant IBS. In the current
    study, the correlation between the amount of methane and the amount of
    constipation was confirmed, another key finding.

    "We were pleased but not surprised with the results of this study," said
    Pimentel. "The next step is to start larger, multi-centered studies to
    confirm the positive results of this study, which suggest that people can
    benefit from targeted antibiotic treatment for their IBS."

    Irritable Bowel Syndrome is an intestinal disorder that causes abdominal
    pain or discomfort, cramping or bloating and diarrhea and constipation. It
    is a long-term condition that usually begins in adolescence or in early
    adult life. Episodes may be mild or severe and may be exacerbated by
    stress. It is one of the top ten most frequently diagnosed conditions among
    U.S. physicians and affects women more often than men.

    Other authors from Cedars-Sinai include Sandy Park, B.A., Yuthana Kong
    M.P.H. and Robert Wade. Sunanda V. Kane from the University of Chicago also
    participated in the study.

    Rifaximin is made by Salix Pharmaceuticals, Inc. Funding for the study was
    provided by Salix Pharmaceuticals, Inc.
  2. earn

    earn New Member

    Thank you so much for that information. I am going to ask my gastro dr about it-fo me to try--